ARTICLES BY LOUIS

• Sanofi-Genzyme Together On CMO Reputation Management

  Not long after Sanofi tied the knot with Genzyme in 2011, Piet Houwen was asked to lead contract-manufacturing operations. Now about 5 years into the marriage, I visit with Houwen to learn about this combination of Big Pharma and Big Bio, his role, and an attitudinal adjustment for better biologics outsourcing.

• Comfortable CMO Consolidation And Biopharma Convergence

  The biopharma industry has been calling for more consolidation and convergence in the CRO, CDMO and CMO market. Well, we are now getting our share of it. And it is bringing on some creative deal-making, and unexpected developments. But we seem comfortable with what is transpiring. Here’s why.

• Most Of What I Know About CMC I Learned At A CDMO

  How does the modern-day CMC leader at drug sponsors get the job done? Michael Markey, newly appointed CMC Director, Pharmaceutical Sciences, Radius Health, Inc., says applying past experiences from working at CDMOs helps. However, there’s a lesson he’s learned since joining Radius, and it has to do with branding and the marketing of contract services.

• Outsourced Pharmaceutical Manufacturing Grows To $76 Billion

  The outsourced manufacturing sector should continue its growth at a clip of 6.6% over the next five years, faster than the projected annual growth rate of the overall pharmaceutical industry (5.5%). That’s according to a new report from Results Healthcare, Pharma & Biotech 2017 Review of outsourced manufacturing.

• Novartis And The Arrival Of The Continuous Manufacturing Facility

  The journey to implementation of the disruptive technology of continuous manufacturing began in 2005, according to Markus Krumme of Novartis, with a single question on a slide presented to Novartis development and manufacturing executives. “Why don’t we have facilities that can continuously produce materials?” then-CEO Daniel Vasella asked.